Pfizer Inc. (NYSE:PFE – Get Free Report)’s stock price was down 2.4% during trading on Monday . The company traded as low as $23.62 and last traded at $23.74. Approximately 58,429,589 shares were traded during mid-day trading, an increase of 36% from the average session volume of 42,859,461 shares. The stock had previously closed at $24.32.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on PFE. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday. Guggenheim raised their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.59.
Read Our Latest Stock Analysis on Pfizer
Pfizer Trading Down 2.4%
Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s payout ratio is 131.30%.
Hedge Funds Weigh In On Pfizer
A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Horizon Financial Services LLC grew its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new position in Pfizer during the fourth quarter valued at about $26,000. YANKCOM Partnership purchased a new stake in Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC increased its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. raised its position in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
